Tina Vilsbøll

Tina Vilsbøll

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


  1. Published

    The glucose-lowering effect of the bile acid sequestrant sevelamer in patients with type 2 diabetes is not mediated by glucagon-like peptide 1

    Nerild, H. H., Brønden, Andreas, Haddouchi, A. E., Holst, Jens Juul, Sonne, D. P., Vilsbøll, Tina & Knop, Filip Krag, 2021, In: Diabetologia. 64, SUPPL 1, p. 217-217 422.

    Research output: Contribution to journalConference abstract in journalResearch

  2. Published

    The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

    Hare, K. J., Vilsbøll, Tina, Asmar, M., Deacon, Carolyn F., Knop, Filip Krag & Holst, Jens Juul, 1 Jul 2010, In: Diabetes. 59, 7, p. 1765-70 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes

    Hædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., Forman, Julie Lyng, Holst, Jens Juul, Knop, Filip Krag & Vilsbøll, Tina, 2022, In: European Journal of Endocrinology. 187, 4, p. 507-518 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

    Andreasen, C. R., Andersen, A. & Vilsbøll, Tina, 2023, In: Diabetologia. 66, p. 1846-1858 13 p.

    Research output: Contribution to journalReviewResearchpeer-review

  5. Published

    The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

    Vilsbøll, Tina, Agersø, H., Lauritsen, T., Deacon, Carolyn F., Aaboe, K., Madsbad, Sten, Krarup, T. & Holst, Jens Juul, 2006, In: Regulatory Peptides. 137, 3, p. 168-72 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Heimburger, S. M., Brønden, Andreas, Johansen, N. J., Dejgaard, T. F., Vilsbøll, Tina & Knop, Filip Krag, 2019, In: Expert Opinion on Pharmacotherapy. 20, 5, p. 501-510

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    The effects of glucagon-like peptide-1 on the beta cell

    Vilsbøll, Tina, 2009, In: Diabetes, Obesity and Metabolism. 11 Suppl 3, p. 11-18 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    The effects of dual GLP-1/GIP receptor agonism on glucagon secretion: a review

    Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, Mikkel Bring, Vilsbøll, Tina & Knop, Filip Krag, 2019, In: International Journal of Molecular Sciences. 20, 17, 18 p., 4092.

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

    Grøndahl, M. F. G., Bagger, J. I., Suppli, M. P., van Hall, Gerrit, Albrechtsen, Nicolai Jacob Wewer, Holst, Jens Juul, Vilsbøll, Tina, Christensen, Mikkel Bring, Lund, A. B. & Knop, Filip Krag, 2024, In: Endocrine Connections. 13, 3, 7 p., e230516.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: Protocol for a randomised, double-blinded, placebo-controlled trial

    Larsen, E. L., Cejvanovic, V., Kjær, L. K., Vilsbøll, Tina, Knop, Filip Krag, Rungby, Jørgen & Poulsen, Henrik Enghusen, May 2017, In: BMJ Open. 7, 5, 6 p., e014728.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...42 Next

ID: 33056950